UNSPSC 51271632: Octacaine hydrochloride

This classification denotes an anesthetic agent C14H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9HKU5M1CEM, chemically known as butanamide, 3-(diethylamino)-n-phenyl-, hydrochloride (1:1), but more generally known as octacaine hydrochloride, which bears US NIH Compound Identifier 159597. Most nations, for tariff and trade purposes, schedule octacaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, OCTACAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CCN(CC)C(C)CC(=O)NC1CCCCC1.CL.

UNSPSC 51271632 Octacaine hydrochloride is a Commodity code covering local anesthetic pharmaceutical products. State and local government procurement activity under this code centers on generic and branded pharmaceuticals sourced through cooperative purchasing agreements that serve hospitals, clinics, correctional facilities, and other public health and human-service agencies. The issuing bodies soliciting under this code are primarily multistate cooperative purchasing alliances administering contracts on behalf of member state agencies and subordinate jurisdictions. The scope of work involves manufacturers and authorized distributors establishing supply contracts for identified pharmaceutical products with specific formulations, dosages, and National Drug Codes, with vendors required to maintain relationships with established pharmaceutical wholesalers, meet FDA compliance and Good Manufacturing Practice (cGMP) certification, and adhere to Drug Supply Chain Security Act (DSCSA) requirements. Pricing submissions typically use net-price formats, WAC-minus structures, or flat-price models, with evaluation weighted heavily on price competitiveness and compliance with administrative fee and electronic data interchange requirements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (RFP) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. MMCAP coordinates purchasing across participating state and local government facilities in Minnesota and Oregon, requiring awarded vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contracts effective July 1, 2026. Vendors must carry comprehensive insurance including $5,000,000 commercial general liability coverage, maintain compliance with FDA expiration-date and shelf-life standards, and accept a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation. No specific award value or budget range was disclosed; incumbent responders' agreements will extend through June 30, 2028.